论文部分内容阅读
目的评价伊立替康联合顺铂化疗对局部晚期食管癌患者的疗效及其毒副反应。方法选取本科2008年6月至2010年11月收治的52例初治食管癌患者资料,病理证实为鳞状细胞癌或腺癌,无远处转移。伊立替康65 mg/m2d1、8;顺铂25 mg/m2d1、2、8、9;21 d为1周期,化疗期间常规积极对症支持治疗,每个患者完成至少2周期化疗后评价疗效。结果 52例均接受至少2周期的化疗,共完成186个周期的化疗。病例均可评价疗效及不良反应,完全缓解(CR)1例(1.9%),部分缓解(PR)21例(40.4%),有效率为42.3%;中位疾病进展时间5.8个月,中位生存时间为11.6个月。主要不良反应为粒细胞减少、腹泻、恶心、呕吐等,Ⅲ～Ⅳ级不良反应发生率较低。结论伊立替康联合顺铂化疗对局部晚期食管癌效果较好,且患者对副反应的耐受良好。
Objective To evaluate the efficacy and toxicity of irinotecan combined with cisplatin chemotherapy in patients with locally advanced esophageal cancer. Methods The data of 52 newly diagnosed esophageal cancer patients admitted from June 2008 to November 2010 were selected. The pathology was confirmed as squamous cell carcinoma or adenocarcinoma without distant metastasis. Irinotecan 65 mg / m2d1,8; cisplatin 25 mg / m2d1,2,8,9; 21 d for a period of chemotherapy during active symptomatic and symptomatic supportive treatment, each patient completed at least 2 cycles after chemotherapy to evaluate the efficacy. Results All of the 52 patients received at least 2 cycles of chemotherapy and completed 186 cycles of chemotherapy. Efficacy and adverse reactions were evaluated in all cases. One patient (1.9%) had complete remission (CR), 21 (40.4%) had partial response (PR), and the effective rate was 42.3%. The median progression time was 5.8 months Survival time is 11.6 months. The main adverse reactions were neutropenia, diarrhea, nausea, vomiting, Ⅲ - Ⅳ grade adverse reactions were lower. Conclusion The irinotecan combined with cisplatin chemotherapy is better than locally advanced esophageal cancer and the patients are well tolerated.